Newer antidiabetic agents including SGLT1/2 (sodium-glucose co- transporter-1/2) inhibitors and GLP-1R (glucagon-like peptide 1 receptor) agonists are being tested in NASH. Here, SLC5A1 is linked to metabolic dysfunction-associated steatohepatitis.